Athersys Stock Forecast, Price & News

Athersys (NASDAQ:ATHX) Frequently Asked Questions

Is Athersys a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Athersys stock.
View analyst ratings for Athersys or view top-rated stocks.

What stocks does MarketBeat like better than Athersys?

Wall Street analysts have given Athersys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athersys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Athersys.

How can I listen to Athersys' earnings call?

Athersys will be holding an earnings conference call on Monday, November 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 416-621-4642 with passcode "6652068".

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Sunday, August, 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10).
View Athersys' earnings history.

How has Athersys' stock price been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has decreased by 3.1% and is now trading at $1.24.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ATHX?

1 brokerages have issued 1-year target prices for Athersys' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Athersys' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 303.2% from the stock's current price.
View analysts' price targets for Athersys or view top-rated stocks among Wall Street analysts.

Who are Athersys' key executives?

Athersys' management team includes the following people:

• William B. J. Lehmann, President, Chief Executive & Operating Officer (LinkedIn Profile)
• Ivor MacLeod, Chief Financial & Accounting Officer
• John J. Harrington, Director, Chief Scientific Officer & Executive VP (LinkedIn Profile)
• Rakesh Ramachandran, Head-Information Technology & Communications
• Eric Jenkins, Senior Director-Medical & Head-Clinical Operations

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Athersys' key competitors?

Some companies that are related to Athersys include PMV Pharmaceuticals (PMVP), Revance Therapeutics (RVNC), Olema Pharmaceuticals (OLMA), Merus (MRUS), Arcutis Biotherapeutics (ARQT), Heron Therapeutics (HRTX), Zymeworks (ZYME), Endo International (ENDP), Atea Pharmaceuticals (AVIR), Vanda Pharmaceuticals (VNDA), CannTrust (CNTTF), Prometheus Biosciences (RXDX), FibroGen (FGEN), Northwest Biotherapeutics (NWBO) and Aclaris Therapeutics (ACRS).
View all of ATHX's competitors.

What other stocks do shareholders of Athersys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include NEXT Financial Group Inc (0.11%), Green Alpha Advisors LLC (0.08%), Livingston Group Asset Management CO operating as Southport Capital Management (0.02%) and Private Advisor Group LLC (0.01%). Company insiders that own Athersys stock include John J Harrington, John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends for Athersys.

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including Livingston Group Asset Management CO operating as Southport Capital Management , and NEXT Financial Group Inc. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr.
View insider buying and selling activity for Athersys or view top insider-selling stocks.

Which major investors are buying Athersys stock?

ATHX stock was acquired by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, and Green Alpha Advisors LLC.
View insider buying and selling activity for Athersys or or view top insider-buying stocks.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.24.

How much money does Athersys make?

Athersys has a market capitalization of $280.56 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78.76 million in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 97 workers across the globe.

When was Athersys founded?

Athersys was founded in 1995.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

Where are Athersys' headquarters?

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at (216) 431-9900 or via email at [email protected].